Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Sellers Decreased Their Shorts By 1.49% As Of Apr 17, 2018

April 17, 2018 - By Andrea Pope

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Corporate Logo

Change of 1.49% for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s short interest was registered. It was published in April by FINRA the 3.39M short interest on ADMP. That’s 1.49% down from 3.45M shares. 7 days will cost ADMP With 496,400 average volume to restore its previous position. Adamis Pharmaceuticals Corporation’s short interest float is 11.61%.

ADMP reached $3.65 on during the last trading session after $0.05 change.Adamis Pharmaceuticals Corporation has volume of 255,435 shares. Since April 17, 2017 ADMP has declined 20.00% and is downtrending. ADMP underperformed the S&P500 by 31.55%.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States.The firm is worth $121.87 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease.Currently it has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

In total 3 analysts cover Adamis Pharma (NASDAQ:ADMP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $9.5 highest and $6.25 lowest [Target] Adamis Pharma has $7.58 average [Target] or 107.67% above the current ($3.65) price. 3 are the (NASDAQ:ADMP)’s analyst reports since November 15, 2017 according to StockzIntelligence Inc. On Monday, December 4 Raymond James maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating. Raymond James has “Buy” rating and $7.0 target. On Friday, March 23 B. Riley & Co maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) with “Buy” rating.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: